Kolorektal Kanser Karaciğer Metastazlarında Yttrıum 90 ile Radyoembolizasyonun Orta ve Uzun Dönem Etkinliğinin Değerlendirilmesi

Abstract

Purpose: The aim of this study was to establish the efficacy of radioembolization with Yttrium 90 in chemotherapy resistant, inoperable hepatic metastatic colorectal carcinoma patients. Material-Methods: 48 hepatic-dominant metastatic colorectal patients who underwent radioembolization with Yttrium 90 between September 2008- May 2014 were included in this study. The patients were evaluated by CT, MRI or PET-CT before and after the procedure at regular intervals. Results: In all patients who had radioembolization post-procedural overall survival was 12.8 months, time to progression was 2.8 months. Since the patients had RE at advanced stage, 58% of patients could not have their chemotherapy after the procedure. Nevertheless, median survival after metastasis was 32.8 months. Conclusions: Radioembolization is a safe local-regional treatment option in patients with chemotherapy resistant, inoperable hepatic metastatic colorectal carcinoma patients. In our study, radioembolization had a survival of 12.8 months in salvage therapy of chemotherapy resistant, advanced stage hepatic dominant colorectal carcinoma patients with a very low toxicity. Radioembolization treatment at an earlier stage may lead to favourable results in the management of hepatic metastatic colorectal carcinoma. Nevertheless, in order to better establish the efficacy of radioembolization and its role in the management, extensive prospective studies are needed in the future.